A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09

Duchesne, Gillian; Bolger, J. J.; Griffiths, Gareth; Roberts, J.T.; Graham, John D.; Hoskin, Peter; Fosså, Sophie D.; Uscinska, Barbara; Parmar, Mahesh

doi:10.1016/s0360-3016(00)00430-2

Cited by 130 publications

(103 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ECOG PS defined which schedule would be assigned: More severe patients (ECOG > 2) underwent the hypofractionated group B procedure. Group B patients were therefore less subjected to transportation, with less impact on their quality of life, and alleged non--inferior efficacy (4,19,26).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery

et al. 2013

View full text Add to dashboard Cite

Objective: The aim of our study was to assess short and mid-term clinical efficacy of external beam radiation therapy to achieve hemostasis in patients with bladder-cancer related gross hematuria who were unfit for surgery. We also assessed hypofractionation as a possible alternative option for more severe patients. Patients and Methods: Thirty-two patients were included for hemostatic radiation therapy, with two schedules based on Eastern Cooperative Oncology Group performance status. The standard treatment was 30 Gy in 10 fractions over 2 weeks. More severe patients underwent a hypofractionated regimen, with 20 Gy in 5 fractions over a one week period. Clinical evaluation was performed at 2 weeks and 6 months. Results: At 2 weeks, 69% of patients were hematuria-free. Subgroup analysis showed that 79% of patients undergoing hypofractionated regimen were hematuria-free. A total of 54% were hematuria-free with the standard regimen. Based on tumor stage, hematuria was controlled at 2 weeks for 57% of non-muscle invasive tumors and 72% of muscle--invasive tumors. After 6 months, 69% of patients had relapsed, regardless of tumor stage or therapy schedules. Conclusions: Hemostatic radiotherapy is an effective option for palliative-care hematuria related to bladder cancer in patients unfit for surgery. Although it appears to be rapidly effective, its effect is of limited duration. Hypofractionation also seems to be an effective option; however larger cohorts and prospective trials are needed to evaluate its efficacy compared to standard schedules.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, the optimal schedule for palliative EBRT in bladder tumors unfit for surgery remains a matter of debate (4).…”

Section: Introductionmentioning

confidence: 99%

The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery

et al. 2013

View full text Add to dashboard Cite

show abstract

“…8 A large multi-centre trial demonstrated symptomatic improvement, such as hematuria, urinary frequency, dysuria or nocturia, in 68% of patients deemed unsuitable for curative treatment. 9 The usefulness of palliative radiotherapy, however, must be considered within the context of the transitory symptomatic improvement and the poor survival for these patients.…”

Section: Months)mentioning

confidence: 99%

Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy

Svatek

Siefker‐Radtke

Dinney

2013

CUAJ

View full text Add to dashboard Cite

Metastatic or unresectable disease is identified in approximately 20% of patients presenting with invasive urothelial cancer. In addition, up to 50% of patients will develop metastases following radical cystectomy for clinically localized disease. Multiagent cisplatin-based chemotherapy is considered standard first-line treatment for these patients. Although urothelial cancer is considered a chemosensitive tumour, metastatic disease is associated with poor prognosis and short-term survival. Here, we review the role of a multidisciplinary approach to treating patients with metastatic urothelial cancer.

show abstract

“…Представлены результаты применения различных режимов ГФ: РОД 8,5-7,0 Гр, 2-3 фракции до СОД 17-21 Гр [8][9][10][11]; РОД 5-6 Гр, 1 или 2 фракции в неде-лю до СОД 30-36 Гр [12][13][14][15][16]; а также РОД 3,0-3,5 Гр, 10 фракций до СОД 30-35 Гр [9,17,18]. Как следует из опубликованных данных, применение подобных схем ДЛТ у больных РМП позволяет достичь палли-ативного эффекта в 40-70 % случаев.…”

Section: Introductionunclassified

“…[9]. В него были включены 500 больных РМП в целях проведения сравнительного анализа эффек-тивности и токсичности 2 режимов ГФ при реализа-ции паллиативной ДЛТ:…”

Section: Introductionunclassified

Palliative radiation therapy of bladder cancer

2017

View full text Add to dashboard Cite

show abstract

A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09

Cited by 130 publications

References 9 publications

The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery

The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery

Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy

Palliative radiation therapy of bladder cancer

Contact Info

Product

Resources

About